Idoya Lahortiga

Summary

Affiliation: University of Navarra
Country: Spain

Publications

  1. ncbi NUP98 is fused to HOXA9 in a variant complex t(7;11;13;17) in a patient with AML-M2
    Idoya Lahortiga
    Department of Genetics, School of Science, University of Navarra, C Irunlarrea s n, 31008 Pamplona, Spain
    Cancer Genet Cytogenet 157:151-6. 2005
  2. ncbi FISH analysis of hematological neoplasias with 1p36 rearrangements allows the definition of a cluster of 2.5 Mb included in the minimal region deleted in 1p36 deletion syndrome
    Idoya Lahortiga
    Laboratory of Genetics, Division of Oncology, Center for Applied Medical Research CIMA, University of Navarra, Pio XII, 55, 31080, Pamplona, Spain
    Hum Genet 116:476-85. 2005
  3. ncbi Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells
    Idoya Lahortiga
    Department of Genetics, University of Navarra, C Irunlarrea s n, Pamplona 31008, Spain
    Oncogene 23:311-6. 2004
  4. ncbi NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder
    Jose L Vizmanos
    Department of Genetics, University of Navarra, Pamplona, Spain
    Cancer Res 64:2673-6. 2004
  5. ncbi Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements
    Idoya Lahortiga
    Department of Genetics, University of Navarra, Pamplona, Spain
    Genes Chromosomes Cancer 40:179-89. 2004
  6. ncbi NUP98 is fused to adducin 3 in a patient with T-cell acute lymphoblastic leukemia and myeloid markers, with a new translocation t(10;11)(q25;p15)
    Idoya Lahortiga
    Department of Genetics, University of Navarra, 31008 Pamplona, Spain
    Cancer Res 63:3079-83. 2003
  7. ncbi t(10;16)(q22;p13) and MORF-CREBBP fusion is a recurrent event in acute myeloid leukemia
    Jose L Vizmanos
    Department of Genetics, School of Science, University of Navarra, C Irunlarrea s n, 31080 Pamplona, Spain
    Genes Chromosomes Cancer 36:402-5. 2003
  8. ncbi Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib
    Xabier Agirre
    Area of Cancer, Area of Cell Therapy and Hematology Service, University Clinic, University of Navarra and Foundation for Applied Medical Research, Avda Pio XII 36, Pamplona, Spain
    Cancer Genet Cytogenet 160:22-6. 2005
  9. ncbi TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia
    Xabier Agirre
    Department of Genetics, School of Sciences, University of Navarra, Pamplona, Navarra, Spain
    Mol Carcinog 38:201-8. 2003
  10. ncbi Molecular cytogenetic characterization of breakpoints in 19 patients with hematologic malignancies and 12p unbalanced translocations
    Maria D Odero
    Department of Genetics, University of Navarra, C Irunlarrea s n, 31008, Pamplona, Spain
    Cancer Genet Cytogenet 142:115-9. 2003

Collaborators

Detail Information

Publications23

  1. ncbi NUP98 is fused to HOXA9 in a variant complex t(7;11;13;17) in a patient with AML-M2
    Idoya Lahortiga
    Department of Genetics, School of Science, University of Navarra, C Irunlarrea s n, 31008 Pamplona, Spain
    Cancer Genet Cytogenet 157:151-6. 2005
    ..To our knowledge, this is the first t(7;11) variant involving NUP98 described in hematological malignancies...
  2. ncbi FISH analysis of hematological neoplasias with 1p36 rearrangements allows the definition of a cluster of 2.5 Mb included in the minimal region deleted in 1p36 deletion syndrome
    Idoya Lahortiga
    Laboratory of Genetics, Division of Oncology, Center for Applied Medical Research CIMA, University of Navarra, Pio XII, 55, 31080, Pamplona, Spain
    Hum Genet 116:476-85. 2005
    ..5 Mb of the complete 1p36 band. This could explain its proneness for involvement in chromosomal rearrangements in hematological neoplasias...
  3. ncbi Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells
    Idoya Lahortiga
    Department of Genetics, University of Navarra, C Irunlarrea s n, Pamplona 31008, Spain
    Oncogene 23:311-6. 2004
    ..The clinicopathological features and the breakpoint on 1p36 are different from cases previously described, and MEL1 is not overexpressed, suggesting a heterogeneity in myeloid neoplasias with t(1;3)...
  4. ncbi NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder
    Jose L Vizmanos
    Department of Genetics, University of Navarra, Pamplona, Spain
    Cancer Res 64:2673-6. 2004
    ..After treatment with imatinib, the patient achieved hematological and cytogenetical remission, but NIN-PDGFRB mRNA remained detectable by reverse transcription-PCR...
  5. ncbi Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements
    Idoya Lahortiga
    Department of Genetics, University of Navarra, Pamplona, Spain
    Genes Chromosomes Cancer 40:179-89. 2004
    ..Our data suggest that a unique mechanism is not likely to be involved in 3q21q26 rearrangements...
  6. ncbi NUP98 is fused to adducin 3 in a patient with T-cell acute lymphoblastic leukemia and myeloid markers, with a new translocation t(10;11)(q25;p15)
    Idoya Lahortiga
    Department of Genetics, University of Navarra, 31008 Pamplona, Spain
    Cancer Res 63:3079-83. 2003
    ..This region is always retained in the fusion transcript with the NH(2) terminus FG repeats of NUP98, suggesting an important role in the mechanism of leukemogenesis...
  7. ncbi t(10;16)(q22;p13) and MORF-CREBBP fusion is a recurrent event in acute myeloid leukemia
    Jose L Vizmanos
    Department of Genetics, School of Science, University of Navarra, C Irunlarrea s n, 31080 Pamplona, Spain
    Genes Chromosomes Cancer 36:402-5. 2003
    ..This supports that this is a recurrent pathogenic translocation in AML...
  8. ncbi Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib
    Xabier Agirre
    Area of Cancer, Area of Cell Therapy and Hematology Service, University Clinic, University of Navarra and Foundation for Applied Medical Research, Avda Pio XII 36, Pamplona, Spain
    Cancer Genet Cytogenet 160:22-6. 2005
    ..Loss of normal BCR in one cell clone may contribute to the resistance to imatinib due to the lack of BCR mediated inhibition of BCR-ABL1...
  9. ncbi TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia
    Xabier Agirre
    Department of Genetics, School of Sciences, University of Navarra, Pamplona, Navarra, Spain
    Mol Carcinog 38:201-8. 2003
    ..Using these techniques, we have found promoter methylation in 32% of the cases, missense mutations in 8.8%, and deletion of one allele in 7.5% of the samples, with TP53 being altered in 40% of the ALL samples studied in this series...
  10. ncbi Molecular cytogenetic characterization of breakpoints in 19 patients with hematologic malignancies and 12p unbalanced translocations
    Maria D Odero
    Department of Genetics, University of Navarra, C Irunlarrea s n, 31008, Pamplona, Spain
    Cancer Genet Cytogenet 142:115-9. 2003
    ..In these four cases and in two others (6/19, 31.5%), the fusion with the partner chromosome was in the subtelomeric region of 12p13.3, confirming that there is a recurrent breakpoint in this region...
  11. ncbi Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia
    Xabier Agirre
    Foundation for Applied Medical Research, Division of Cancer, Area of Cell Therapy and Hematology Service, Clinica Universitaria, Universidad de Navarra, Pamplona, Spain
    Int J Cancer 118:1945-53. 2006
    ....
  12. ncbi A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome
    Maria D Odero
    Department of Genetics, University of Navarra, Pamplona, Spain
    Genes Chromosomes Cancer 35:11-9. 2002
    ..Possible mechanisms to account for the development of MDS in this patient are discussed...
  13. pmc Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia
    Iria Vázquez
    Division of Oncology, CIMA, University of Navarra, Pamplona, Spain
    Haematologica 96:1448-56. 2011
    ..Over-expression of EVI1 through either 3q26 rearrangements, MLL fusions, or other unknown mechanisms confers a poor prognosis in acute myeloid leukemia...
  14. ncbi Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes
    Borja Saez
    Institute of Human Genetics, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
    Cancer Genet Cytogenet 175:65-8. 2007
    ..Moreover, the upregulated oncogenes differed between both samples. Thus, biallelic IGH translocations might exert different pathogenetic effects in plasma cell disorders...
  15. doi In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia
    Kim De Keersmaecker
    Human Genome Laboratory, Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium
    Haematologica 93:533-42. 2008
    ....
  16. doi Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion
    Idoya Lahortiga
    Human Genome Laboratory, Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium
    Haematologica 93:49-56. 2008
    ..We report an unusual case of a patient presenting with peripheral basophilia and systemic mastocytosis in whom cytogenetic analysis revealed a t(4;5)(q21.1;q31.3)...
  17. pmc Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice
    Danielle C Shing
    Department of Experimental Oncology, European Institute of Oncology, Milan, Italy
    J Clin Invest 117:3696-707. 2007
    ..Thus, overexpression of sPRDM16 induces abnormal growth of stem cells and progenitors and cooperates with disruption of the p53 pathway in the induction of myeloid leukemia...
  18. ncbi Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia
    Idoya Lahortiga
    Human Genome Laboratory, Department of Molecular and Developmental Genetics, Vlaams Instituut voor Biotechnologie VIB, Leuven, Belgium
    Nat Genet 39:593-5. 2007
    ..Our results identify duplication of MYB as an oncogenic event and suggest that MYB could be a therapeutic target in human T-ALL...
  19. ncbi The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors
    Els Lierman
    Department of Molecular and Developmental Genetics, Flanders Interuniversity Institute for Biotechnology VIB, University of Leuven, Leuven, Belgium
    Haematologica 92:27-34. 2007
    ..We investigated the efficacy of sorafenib at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies...
  20. ncbi Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders
    E Joanna Baxter
    Wessex Regional Genetics Laboratory, Salisbury District Hospital, UK
    Br J Haematol 120:251-6. 2003
    ..Our data indicate that several PDGFRB partner genes remain to be characterized...
  21. ncbi Remission of acute monocytic leukemia, secondary to treatment with epipodophyllotoxins, in a patient with t(8;16)(p11;p13) and MYST3-CREBBP fusion
    Jose L Vizmanos
    Cancer Genet Cytogenet 152:177-8. 2004
  22. ncbi A new complex rearrangement involving the ETV6, LOC115548, and MN1 genes in a case of acute myeloid leukemia
    Elena Belloni
    IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy
    Genes Chromosomes Cancer 41:272-7. 2004
    ..This study lends further support to the hypothesis that gene disruption resulting in either loss of function or haploinsufficiency may be relevant in acute myeloid leukemia pathogenesis...
  23. ncbi A novel t(2;3)(p11;q27) in a case of follicular lymphoma
    Cinzia Tapinassi
    IFOM, FIRC Institute for Molecular Oncology Foundation, Via Adamello 16, 20139 Milan, Italy
    Cancer Genet Cytogenet 172:70-3. 2007
    ..To date, eight different rearrangements involving the ABR have been reported. Here, we describe a novel rearrangement involving a t(2;3)(p11;q27) translocation that affects the ABR in an unusual combination with the IGK locus...